Table 1 Clinical trials using autologous bone marrow mononuclear cells in patients with acute myocardial infarction

Meluzin et al. [93]

Dose-dependent improvement of regional myocardial function by PET

Fernandez-Aviles et al. [94]

Decrease in end systolic volume, improvement in regional and global function

Janssens et al. [19]

No effect on global LVEF, but may favourably affect infarct remodelling

Lunde et al. [12] (ASTAMI)

No effect on global LVEF

Schächinger et al. [17] (REPAIR-AMI)

Improvement in global LVEF

Ge et al. [16]

Improvement in LVEF

De Lezo et al. [95]

Improvement in LVEF

Zhan-quan et al. [96]

Improvement in LVEF

Wollert et al. [14] (BOOST)

Improvement in LV systolic function

Lipiec et al. [97]

Improvement in myocardial perfusion with no effect on global LVEF

Huikuri et al. [98] (FINCELL)

Improvement in global LVEF

Kang et al. [99]

Improvement in myocardial perfusion and systolic function

Assmus et al. [10] (TOPCARE-AMI)

Improvement in LVEF

Schächinger et al. [11] (TOPCARE-AMI)

Improvement in EF

Strauer et al. [9]

Reduction in infarct region

Bartunek et al. [100]

Improvement in LVEF

Hirsch et al. [21]

No effect on global or regional LV function

Tendera et al. [20]

No significant improvement in LVEF

Chen et al. [101]

Improvement in LVEF

Yousef et al. [15] (BALANCE)

Improvement in LVEF, exercise capacity and mortality